Therapeutic potential of JAK inhibitors in juvenile idiopathic arthritis-associated uveitis
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Expert review of clinical immunology - 19(2023), 7 vom: 10. Juli, Seite 689-692 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maccora, Ilaria [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antirheumatic Agents |
|---|
| Anmerkungen: |
Date Completed 06.07.2023 Date Revised 18.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/1744666X.2023.2207823 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356179303 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356179303 | ||
| 003 | DE-627 | ||
| 005 | 20231226065919.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/1744666X.2023.2207823 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1187.xml |
| 035 | |a (DE-627)NLM356179303 | ||
| 035 | |a (NLM)37114341 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Maccora, Ilaria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutic potential of JAK inhibitors in juvenile idiopathic arthritis-associated uveitis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.07.2023 | ||
| 500 | |a Date Revised 18.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Baricitinib | |
| 650 | 4 | |a JAK-inhibitor | |
| 650 | 4 | |a JIA | |
| 650 | 4 | |a Uveitis | |
| 650 | 4 | |a pediatric uveitis | |
| 650 | 4 | |a tofacitinib | |
| 650 | 4 | |a treatment | |
| 650 | 4 | |a upadacitinib | |
| 650 | 7 | |a Janus Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 700 | 1 | |a Land, Preston |e verfasserin |4 aut | |
| 700 | 1 | |a Miraldi Utz, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Angeles-Han, Sheila T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of clinical immunology |d 2005 |g 19(2023), 7 vom: 10. Juli, Seite 689-692 |w (DE-627)NLM191372153 |x 1744-8409 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:7 |g day:10 |g month:07 |g pages:689-692 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/1744666X.2023.2207823 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 7 |b 10 |c 07 |h 689-692 | ||